Remdesivir: An Antiviral Drug against SARS-COV-2

Laiba Saleem 1

8th WCPSDM.2021. APR.Published Online 18 APR 2021

Abstract : Coronavirus pandemic has negatively impacted the life of every individual. Researchers around the globe are working tirelessly to develop new diagnostics, vaccines and therapeutics for the prevention and treatment of COVID-19. The drug repurposing of already used medicines has emerged as a realistic and effective strategy to counter this menace in the short run, and several antiviral nucleosides and nucleotides are currently at different stages of clinical trials. Among them, Remdesivir has emerged promising candidate, which was originally evaluated against Ebola virus in 2014. Remdesivir is a nucleotide analogue prodrug which perturbs the viral replication, and therefore, is a suitable candidate for SARS-COV-2 inhibition. Beside Remdesivir repurposing, there is an urgent need of synthesizing new nucleosides and nucleotides molecular libraries, and their screening against coronavirus disease. In this poster we will discuss the synthesis, mode of action, and biological evaluation of Remdesivir, particularly, against SARS-CoV-2 virus.